Priority Assets


Our Priority Assets are largely maturing clinical development companies, nearing significant value inflection points.

Kymab is a clinical-stage bipharmaceutical company based in Cambridge, UK, developing a deep pipeline of novel human antibody-based therapies in a broad range of indications.

Kymab’s unique platforms generate a vast repertoire of fully human, species cross-reactive and affinity-matured antibodies against challenging targets. Kymab is focused on immune mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®.

Kymab, the first spin-out from The Wellcome Trust Sanger Institute, generates product candidates using its proprietary, integrated technology platform. Its IntelliSelect® Transgenic discovery platforms are designed to generate fully human monoclonal antibodies from highly engineered strains of mice that have the complete constellation of human antibody building blocks in their genome. Kymab’s development platforms combine single cell sequencing, genomics and proprietary bioinformatic algorithms to prioritise and select antibodies generated by its discovery platforms that have the most desirable druglike properties.

Together with Kymab’s antibody discovery and development expertise, Kymab’s suite of technologies has enabled the generation of a deep pipeline of product candidates and an expanding discovery pipeline, including both traditional antibodies and bi-specific antibodies.

Alongside its wholly-owned programmes, Kymab has partnered with world-leading scientific and medical collaborators, including Sosei Heptares Therapeutics and the Bill and Melinda Gates Foundation.

Kymab Pipeline

Candidate

Indication

Pre-clinical

Phase 1

Phase 2

Phase 3

KY1005 - Anti-OX40L

Atopic dermatitis

KY1004 - ICOS agonist

Solid tumours

KY1004 - ICOS + anti-PD-L1

Solid tumours

KY1043 - PD-L1 immunocytokine

Solid tumours

KY1049 - Factor VIII-mimetic

Haemophilia A

KY1051 - CXCR-4

Solid tumours

KY1005 - OX40L

Acute Graft-vs-Host-disease & other immune disorders

Candidate: KY1005 - Anti-OX40L

Indication: Atopic dermatitis

Pre-clinical

Phase 1

Phase 2

Phase 3


Candidate: KY1004 - ICOS agonist

Indication: Solid tumours

Pre-clinical

Phase 1

Phase 2

Phase 3


Candidate: KY1004 - ICOS + anti-PD-L1

Indication: Solid tumours

Pre-clinical

Phase 1

Phase 2

Phase 3


Candidate: KY1043 - PD-L1 immunocytokine

Indication: Solid tumours

Pre-clinical

Phase 1

Phase 2

Phase 3


Candidate: KY1049 - Factor VIII-mimetic

Indication: Haemophilia A

Pre-clinical

Phase 1

Phase 2

Phase 3


Candidate: KY1051 - CXCR-4

Indication: Solid tumours

Pre-clinical

Phase 1

Phase 2

Phase 3


Candidate: KY1005 - OX40L

Indication: Acute Graft-vs-Host-disease & other immune disorders

Pre-clinical

Phase 1

Phase 2

Phase 3